Myelosuppression

Myelosuppression occurs when the bone marrow makes too few blood cells to replace the spent blood cells. Myelosuppression is not a painful condition, but it is a serious one, can it can lead to fatigue, excessive bleeding, or an increased vulnerability to certain infections.

These three conditions are a direct result of reduced bone marrow production, as they reflect the shortage of specific blood cells with specific purposes:

-- Anemia is due to a shortage of red blood cells and causes fatigue.

-- Thrombocytopenia, or excessive bleeding, occurs when there is a shortage of platelets.

-- Neutropenia is defined as a shortage of white blood cells, notably neutrophils, and it leaves patients open to the risk of serious infection.

Causes of Myelosuppression

In the context of cancer treatment, myelosuppression is generally a consequence of anti-cancer treatment like chemotherapy. You can look at the side effects of almost any major chemotherapy drug and see 'myelosuppression' listed. Though a serious condition, it is typically not permanent, and when anti-cancer treatments cease, the bone marrow usually returns to its normal production of blood cells.

When cancer treatment causes myelosuppression, the next step is typically at the discretion of the patient's physicians. Responding to myelosuppression may involve halting chemotherapeutic treatment to allow the bone marrow to recover; it may involve a red blood cell transfusion to overcome the effects of anemia, or it may involve an injection of so-called growth factors, that encourage the bone marrow to produce neutrophils.

If myelosuppression is mild, and the patient is not affected, there may be no intervention at all. The decision would be made by the patient's oncology team based on their specific set of circumstances.

To that end, sometimes myelosuppression is treated in a prophylactic manner—meaning before it begins. This can be achieved by using the likes of granulocyte colony-stimulating factor (G-CSF) which can sometimes reduce the severity of the distress on the bone marrow from cancer treatment.

Sources

- Medscape: Chemotherapy-Induced Myelosuppression
- American Cancer Society: Bone marrow suppression

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap